Mad Money Mailbag: High Price to Pay for Bard
A viewer learns Cramer's take on medical devices company C.R. Bard.
Editor's note: The following are questions received from viewers of "Mad Money," seen every day at 6 p.m. EST on CNBC.
I bought C.R. Bardundefined a couple of points ago. Do you have a positive outlook for the stock?-- Tony from Illinois
James J. Cramer:
I believe this is a great medical devices company, though the stock appears somewhat expensive. At around $64 a share, Bard is trading at 21 times earnings, compared with just 15% annual growth potential.
TheStreet Recommends
Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by
.
